Stoxline.com
android_stock_chart
Stock Chart

Stoxline Lite

Stoxline Pro

Option Calculator
Stoxline
Mobile

Home | Charts | Showcases | Stock Ranks | Options | ETFs | Educations

 
Tweet this page
Share on Facebook
Share on Google+

7 Binary Options

atoplab.com
 

Enter Stock Symbol:  

Kala Pharmaceuticals Inc. (KALA)

9.96 0.02 (0.2%)

10-17 12:38

Open:

9.71

Pre. Close:

9.94

High:

10.0394

Low:

9.55

Volume:

234,811

Market Cap:

331M

Stock Price Prediction (Update at 5:00pm est.)

If tomorrow:

Open lower

Open higher

High:

10.225 - 10.267

10.267 - 10.309

Low:

8.84 - 8.878

8.878 - 8.917

Close:

9.871 - 9.944

9.944 - 10.019

Technical analysis  (as of: 2018-10-17 11:17:20 AM)

Overall:

      

Stoxline posted a BUY today, same as yesterday. This stock seems to continue bullish move. If you bought, continue to hold stock until SELL signal. You are relatively safe to buy now, upward move is expected.

Target:

Six months: 13.32     One year: 15.55

Support:

Support1: 9.05    Support2: 7.60

Resistance:

Resistance1: 11.40    Resistance2: 13.32

Pivot:

8.82

Moving Averages:

MA(5): 9.05     MA(20): 9.24

MA(100): 12.20     MA(250): 14.69

MACD:

MACD(12,26): -0.58     Signal(12,26,9): -0.80

%K %D:

%K(14,3): 64.89     %D(3): 47.57

RSI:

RSI(14): 50.33

52-Week:

High: 22.1  Low: 7.6  Change(%): -42.9

Average Vol(K):

3-Month: 37895  10-Days 73691

Strong Sell ★★ Sell ★★★ Neutral ★★★★ Buy ★★★★★ Strong Buy

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
KALA has closed below upper band by 22.2%. Bollinger Bands are 38.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

2018-10-16T09:39:10-04:00
Kala Pharma files U.S. marketing application for KPI-121 for dry eye

2018-10-16T08:00:00-04:00
Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for KPI-121 0.25% for Dry Eye Disease

Financial Analysis

Growth

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.

Profitability

Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.

Solvency

Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.

Efficiency

NA

Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.

Click here to get more fundamental analysis.

 

Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare

Industry:  Biotechnology

Shares Out. (M)

24.61

Shares Float (M)

24.11

% Held by Insiders

% Held by Institutions

71.70

Shares Short (K)

1353

Shares Short Prior Month (K)

Stock Financials

EPS

-2.080

EPS Est. Current Year

-1.920

EPS Est. Next Year

-1.860

EPS Est. Next Quarter

Forward EPS

-2.569

Book Value (p.s.)

2.910

PEG Ratio

0.06

Profit Margin

Operating Margin

Return on Assets (ttm)

-75.9

Return on Equity (ttm)

226.9

Qtrly Rev. Growth

Gross Profit (p.s.)

Sales Per Share

EBITDA (p.s.)

-0.402

Qtrly Earnings Growth

Operating Cash Flow (M)

-37.81

Levered Free Cash Flow (M)

-20.96

Valuation

P/E

-4.67

P/E Growth Ratio

-0.02

P/BV

3.34

P/S

P/CF

-6.33

Dividend Yield

Dividends & Splits

Dividend

Dividend Pay Date

Invalid DateTime.

Ex-Dividend Date

Invalid DateTime.

Forward Dividend

Last Split Date

Last Split Ratio

-1e+010

 

(c) 2006-2017 Stoxline.com | Contact us | NYSE, NASDAQ, AMEX Stock symbols

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.